# Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis

> **NCT00567918** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 52 (actual)

## Conditions studied

- Keratoconjunctivitis
- Conjunctivitis

## Interventions

- **DRUG:** FK506

## Key facts

- **NCT ID:** NCT00567918
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2008-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00567918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00567918, "Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00567918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*